Search

Your search keyword '"Carson, Peter"' showing total 284 results

Search Constraints

Start Over You searched for: Author "Carson, Peter" Remove constraint Author: "Carson, Peter" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
284 results on '"Carson, Peter"'

Search Results

4. Abstract 12936: Quality of Life Assessments as Inclusion Criteria in Heart Failure Clinical Trials

5. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus

7. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy

10. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2

11. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium

14. Design of a “Lean” Case Report Form for Heart Failure Therapeutic Development

15. Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure

16. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial

19. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

20. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation

21. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

22. MP-453090-7 IDENTIFYING PATIENTS WITH LVEF≤55% WHO MAY BENEFIT FROM A PRIMARY PREVENTION ICD USING SEATTLE PROPORTIONAL RISK MODEL FOR MILDLY REDUCED EF (SPRM-MR) IN 14,752 PATIENTS

25. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction

27. Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee

28. Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee

30. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction)

31. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy

32. Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure)

33. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)

35. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

41. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial

42. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

44. Conduct of clinical trials in the era of COVID-19: JACC scientific expert panel

45. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

46. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction:Pooled Analysis of 3 Clinical Trials

47. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

48. Heart Failure Endpoints in Cardiovascular Outcome Trials of SGLT2 inhibitors in Patients with Type 2 Diabetes: A Critical Evaluation of Clinical and Regulatory Issues

49. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues

50. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction

Catalog

Books, media, physical & digital resources